Shares of Kenvue led S&P 500 decliners Tuesday after the consumer health giant's chief executive indicated the firm faces ...

Kenvue Inc. closed 15.38% below its 52-week high of $25.17, which the company achieved on May 8th.

Shares of Kenvue ( NYSE: KVUE) are under pressure Tuesday and experiencing their worst day since splitting from Johnson & ...

Billionaire investor Daniel Loeb's hedge fund Third Point on Thursday detailed the size of its stakes in U.S. Steel and Kenvue , companies that shareholders hope will soon benefit from being bought by ...

Shares of Kenvue fell after the drug maker's chief executive officer said consumers continue to pull back on spending and retailers increasingly destock inventories amid tariff-related macroeconomic ...

I initiate Kenvue with a 'Buy' rating and a $26 fair value, citing its iconic brands and steady dividend appeal. Kenvue's global operations, diversified product lines, and strong R&D enable ...

Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.

Investing.com -- Jefferies believes investors should take advantage of recent weakness in Kenvue (NYSE:KVUE) stock, reiterating a Buy rating and calling the company a “self-help transformation ...

The firm sees valuation upside, pegging Kenvue’s fair value at $27 per share. “As Kenvue’s growth transformation unfolds, we ...

Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since ...

At IMCAS Asia 2025, we’re proud to present new clinical evidence that reflects the needs of today’s consumers and supports ...

The company’s stock movement reflects concerns over the delayed seasonal demand and the broader implications of a challenging retail and tariff environment. These factors are essential for investors ...